风险分析(工程)
计算机科学
医学
运营管理
总体生存率
过程管理
工作(物理)
生存分析
业务
风险评估
可靠性工程
组分(热力学)
患者安全
基线(sea)
作者
Godwin Yung,Kaspar Rufibach,Marcel Wolbers,Mark Yan,Jue Wang
标识
DOI:10.1080/19466315.2026.2637573
摘要
Advances in anticancer therapies have contributed significantly to decreasing death rates in certain disease and clinical settings. However, they have also made it difficult to power a clinical trial in these settings with overall survival (OS) as the primary efficacy endpoint. Therefore, two approaches have recently been proposed for the pre-specified analysis of OS as a safety endpoint. We provide in this paper a simple unifying framework that includes the aforementioned approaches—and a few others—as special cases. By highlighting each approach’s focus, priority, tolerance for risk, and strengths or challenges for practical implementation, this framework can help facilitate discussions between stakeholders on “fit-for-purpose OS data collection and assessment of harm”. We apply this framework to a real clinical trial in large B-cell lymphoma to illustrate its application and value. Several recommendations and open questions are also raised.
科研通智能强力驱动
Strongly Powered by AbleSci AI